VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Fanale on the Potential of Antibody-Drug Conjugates

Michelle A. Fanale, MD
Published: Tuesday, Feb 12, 2013

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Brentuximab vedotin (Adcetris), the first FDA approved antibody-drug conjugate, is indicated to treat patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following progression on prior therapies. In addition to relapsed patients, Fanale anticipates potential for brentuximab as a frontline treatment. She believes the frontline administration of brentuximab plus chemotherapy may have the potential to prevent relapse.

Fanale adds that brentuximab sets the stage for the development of similar drug conjugates. These novel agents could herald a new era in cancer development, similar to the advent of monoclonal antibody therapies.

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Brentuximab vedotin (Adcetris), the first FDA approved antibody-drug conjugate, is indicated to treat patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following progression on prior therapies. In addition to relapsed patients, Fanale anticipates potential for brentuximab as a frontline treatment. She believes the frontline administration of brentuximab plus chemotherapy may have the potential to prevent relapse.

Fanale adds that brentuximab sets the stage for the development of similar drug conjugates. These novel agents could herald a new era in cancer development, similar to the advent of monoclonal antibody therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x